Efectos nucleares del receptor Tirosina Quinasa ErbB-2 en cáncer de mama

SCHILLACI R; CORDO RUSSO RI; PROIETTI CJ; ELIZALDE PV; CHARREAU EH; CHERVO MF

Prensa Médica Argentina

Ediciones Médicas del Sur SRL

Lugar: Ciudad Autónoma de Buenos Aires; Año: 2017 vol. 103 p. 357 - 364

0032-745X

Membrane overexpression of ErbB-2(MErbB-2), a member of the ErbBs familyof receptor tyrosine kinases, or ErbB-2gene amplification, occurs in 15-20% ofbreast cancers (BC). Until the developmentof MErbB-2-targeted therapies,this BC subtype, called ErbB-2-positive,was associated with increased metastaticpotential and poor prognosis. Although theoverall survival and cure rates have improvedsignificantly with such therapies,resistance to available drugs is still a majorclinical issue. In its classical mechanism,MErbB-2 activates downstream signal-ling cascades, which transduce its effects inBC. The fact that ErbB-2 is also presentat the nucleus of BC cells was discoveredover twenty years ago. Also, compellingevidence revealed a non-canonical functionof nuclear ErbB-2 as a transcriptionalregulator. Since deeper understanding ofnuclear ErbB-2 actions would be criticalto disclose its role as a biomarker and atarget of therapy in BC, we will here reviewits function in BC, focusing on itsrole in growth, metastatic spreading, andresponse to currently available MErbB-2positive BC therapies